Product-led growth for Series B companies: scaling without breaking for healthcare and life sciences in the United Kingdom

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the United Kingdom. In this market, UK buyers reward understatement, credible references, and a pitch that respects their time, so the way you install product-led growth has to be shaped to that reality from day one.

Series B is the stress test for product-led growth. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, self-serve activation to paid conversion, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the United Kingdom it is compounded by the fact that credibility and reference base, not tooling is what actually gates growth. Product-led growth is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of product-led growth is bolting PLG onto a product that requires a demo to understand, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on self-serve activation to paid conversion outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run product-led growth function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the United Kingdom: the healthcare teams that install this get past procurement instead of dying in it, and a single London-anchored win reshapes an entire year of UK pipeline. That is the reason it is worth installing product-led growth deliberately for this market rather than importing a playbook designed for somewhere else.